Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

• Status: Completed
• Trial end date: 1999-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the multiple-dose pharmacokinetic characteristics and pharmacologic activity of gemcabene.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gemphire Therapeutics, Inc.; NeuroBo Pharmaceuticals Inc.

Criteria

Inclusion Criteria:

• Good health as determined by medical history, physical examination, electrocardiogram (ECG), vital signs, and laboratory assessments

• Body weight: 60-100 kg (desirable)

Exclusion Criteria:

• Use of any medication not considered acceptable by the clinical investigators during the 14-day period before the start of the study (Day 1) ;

• Donation of a unit of blood or participation in a study of investigational or marketed drugs during the 30-day period before the start of the study (Day 1);

• If female, of childbearing potential or lactating;

• History of significant reaction to any fibrate lipid-lowering agent; and

• Significant urine collection of any drug which could interfere with the study